Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
immunology and microbiology
Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1
Journal of Virological Methods, Volume 163, No. 2, Year 2010
Notification
URL copied to clipboard!
Description
The introduction of antiretroviral (ARV) therapy in resource-poor settings is effective in suppressing HIV-1 replication and prolonging life of infected individuals. This has led to a demand for affordable HIV-1 drug resistance assays, since treatment failure due to development of drug resistance is common. This study developed and evaluated an affordable "in-house" genotyping assay to monitor HIV-1 drug resistance in Africa, particularly South Africa. An "in-house" assay using automated RNA extraction, and subtype C specific PCR and sequencing primers was developed and successfully evaluated 396 patient samples (viral load ranges 1000-1.6 million RNA copies/ml). The "in-house" assay was validated by comparing sequence data and drug resistance profiles from 90 patient and 10 external quality control samples to data from the ViroSeq™ HIV-1 Genotyping kit. The "in-house" assay was more efficient, amplifying all 100 samples, compared to 91 samples using Viroseq. The "in house" sequences were 99.2% homologous to the ViroSeq sequences, and identical drug resistance mutation profiles were observed in 96 samples. Furthermore, the "in-house" assay genotyped 260 of 295 samples from seven African sites, where 47% were non-subtype C. Overall, the newly validated "in-house" drug resistance assay is suited for use in Africa as it overcomes the obstacle of subtype diversity. © 2009 Elsevier B.V. All rights reserved.
Authors & Co-Authors
Wallis, Carole Lorraine
South Africa, Johannesburg
University of the Witwatersrand
Papathanasopoulos, Maria
South Africa, Johannesburg
University of the Witwatersrand
Lakhi, Shabir
Zambia, Lusaka
Zambia-emory Hiv Research Project
Karita, Etienne
Rwanda, Kigali
Project San Francisco
Kamali, Anatoli
Uganda, Entebbe
Mrc
Kaleebu, Pontiano P.
Uganda, Entebbe
Mrc
Sanders, Eduard Joachim
Kenya, Kilifi
Centre for Geographic Medicine Research
Anzala, Aggrey Omu
Kenya, Nairobi
Kenya Aids Vaccine Initiative
Bekker, Linda-Gail Gail
South Africa, Cape Town
Desmond Tutu Health Foundation
Stevens, Gwynn
Unknown Affiliation
Wit, Tobias F.Rinke De
Netherlands, Amsterdam
Pharmaccess Foundation
Stevens, Wendy Susan
South Africa, Johannesburg
University of the Witwatersrand
South Africa, Johannesburg
National Health Laboratory Service
Statistics
Citations: 62
Authors: 12
Affiliations: 10
Identifiers
Doi:
10.1016/j.jviromet.2009.11.011
ISSN:
01660934
Research Areas
Cancer
Health System And Policy
Infectious Diseases
Study Locations
South Africa